Iwatsubo T, Suzuki H, Sugiyama Y
Drug Metabolism Laboratories, Yamanouchi Pharmaceutical Co., Ltd., 1-1-8, Azusawa, Itabashi-ku, Tokyo, 174, Japan.
J Pharmacol Exp Ther. 1997 Nov;283(2):462-9.
The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-L-tartarate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs. The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, respectively, 300 and 18 times more than that already reported in humans. We have previously reported successful attempts to predict the in vivo hepatic metabolic clearance of YM796 from in vitro data in humans. In our study, the in vitro metabolism of YM796 was determined using liver microsomes prepared from both rats and dogs and we also investigated if the species difference observed in vivo could be quantitatively reproduced in vitro. In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 microM and a Vmax of 520 nmol/min/g liver. However, in dogs, total metabolite formation could be described by three components, as also reported for humans. The Km and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, respectively, 8.1 and 1.7 microM, and 10.9 and 1.2 nmol/min/g liver. The overall intrinsic metabolic clearances estimated from the in vitro studies (CLint,in vitro) for rats and dogs were 38.8 and 2.6 ml/min/g liver, respectively, being approximately 40 and 3 times more than that previously reported for humans (0.94 ml/min/g liver). The overall intrinsic hepatic clearances (CLint,in vivo) calculated from in vivo CLoral were 30.4, 3.4 and 0.73 ml/min/g liver for rats, dogs and humans, respectively, indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metabolism data in each species. Thus, the pronounced species difference in the metabolic clearance observed in vivo can be quantitatively predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmax values.
作为抗痴呆药物正在研发的(S)-(-)-2,8-二甲基-3-亚甲基-1-氧杂-8-氮杂螺[4,5]癸烷-L-酒石酸盐一水合物(YM796),以1mg/kg的剂量口服给药后,在大鼠体内的生物利用度非常低(3.4%),但在犬体内则显著更高(16.1%)。大鼠和犬的口服清除率(CLoral,剂量/AUCoral)分别比已报道的人体值高300倍和18倍。我们之前曾报道过成功从人体体外数据预测YM796体内肝脏代谢清除率的尝试。在我们的研究中,使用大鼠和犬制备的肝微粒体测定了YM796的体外代谢情况,并且我们还研究了在体内观察到的种属差异是否能在体外定量重现。在大鼠中,总代谢物形成可用单一组分动力学描述,Km为13.4μM,Vmax为520nmol/min/g肝脏。然而,在犬中,总代谢物形成可用三个组分描述,这在人体中也有报道。犬和人体中高亲和力、低容量组分(Km1和Vmax1)的Km和Vmax值分别为8.1和1.7μM,以及10.9和1.2nmol/min/g肝脏。根据体外研究估算的大鼠和犬的总体内在代谢清除率(CLint,in vitro)分别为38.8和2.6ml/min/g肝脏,分别约为之前报道的人体值(0.